Emerging Immunotherapy for Acute Myeloid Leukemia

Emerging Immunotherapy for Acute Myeloid Leukemia

Several immune checkpoint molecules and immune targets in leukemic cells have been investigated. Recent studies have suggested the potential clinical benefits of immuno-oncology (IO) therapy against acute myeloid leukemia (AML), especially targeting CD33, CD123, and CLL-1, as well as immune checkpoi...

Full description

Bibliographic Details
Main Authors:	Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	International Journal of Molecular Sciences
Subjects:	acute myeloid leukemia (AML) immune check-point inhibitor (ICI) bispecific T-cell engager (BiTE) dual-affinity retargeting (DART) trispecific killer cell engager (TriKE) chimeric antigen receptor (CAR)
Online Access:	https://www.mdpi.com/1422-0067/22/4/1944

Similar Items

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
by: Ying Cheng, et al.
Published: (2020-11-01)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
by: Zong Sheng Guo, et al.
Published: (2020-07-01)

Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
by: Norimichi Hattori, et al.
Published: (2019-04-01)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
by: Cecily Allen, et al.
Published: (2021-05-01)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
by: Margaux Lejeune, et al.
Published: (2020-05-01)

Recent advances on blinatumomab for acute lymphoblastic leukemia
by: Juanjuan Zhao, et al.
Published: (2019-11-01)

Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review)
by: Manon Queudeville, et al.
Published: (2021-06-01)

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
by: Jan P. Bogen, et al.
Published: (2021-05-01)

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
by: Amanda Rosewell Shaw, et al.
Published: (2018-09-01)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
by: Kinan Alhallak, et al.
Published: (2021-06-01)

Recent updates for antibody therapy for acute lymphoblastic leukemia
by: Le Li, et al.
Published: (2020-11-01)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
by: Rebecca Epperly, et al.
Published: (2020-02-01)

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
by: Karie Runcie, et al.
Published: (2018-09-01)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
by: Maciej Kujawski, et al.
Published: (2019-09-01)

Design and Production of Bispecific Antibodies
by: Qiong Wang, et al.
Published: (2019-08-01)

Tiltbar reverse trike : Utveckling och prototyptillverkning
by: Larsson, Fredrik
Published: (2015)

TALENT ENGAGEMENT FRAMEWORK AS A JOURNEY TO PERFORMANCE
by: Maria Jakubik
Published: (2016-10-01)

The landscape of bispecific T cell engager in cancer treatment
by: Shujie Zhou, et al.
Published: (2021-05-01)

DLL3: an emerging target in small cell lung cancer
by: Dwight H. Owen, et al.
Published: (2019-06-01)

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
by: Fa Yang, et al.
Published: (2016-12-01)

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
by: Hanley N. Abramson
Published: (2020-07-01)

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody
by: Xianglei Liu, et al.
Published: (2021-12-01)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
by: Zheng Tian, et al.
Published: (2021-05-01)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
by: Alessandro Satta, et al.
Published: (2019-10-01)

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
by: Ondine Messéant, et al.
Published: (2021-08-01)

Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules
by: Justin Pollara, et al.
Published: (2020-04-01)

Engineering multi-specific antibodies against HIV-1
by: Neal N. Padte, et al.
Published: (2018-08-01)

T Cell–Associated Immunotherapy for Hepatocellular Carcinoma
by: Weijie Ma, et al.
Published: (2017-02-01)

The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells
by: Hannah E. Hughes-Parry, et al.
Published: (2019-12-01)

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
by: Hélène Bonnevaux, et al.
Published: (2021-01-01)

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
by: Jie Liu, et al.
Published: (2021-01-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
by: Fatih M. Uckun, et al.
Published: (2021-08-01)

Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
by: Ulrich Wuellner, et al.
Published: (2015-12-01)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
by: Virginie Nägele, et al.
Published: (2017-05-01)

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy
by: Shao-Li Huang, et al.
Published: (2021-07-01)

Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors
by: Vladimir Voynov, et al.
Published: (2020-11-01)

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
by: Eleanor M. Scott, et al.
Published: (2019-11-01)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
by: Mingpeng Fu, et al.
Published: (2019-06-01)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
by: Julien Edeline, et al.
Published: (2021-04-01)

Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction
by: Hongbing Yang, et al.
Published: (2018-12-01)